DR AGARWALS HEALTH CARE L vs SUN PHARMACEUTICAL IND L

A side-by-side comparison of DR AGARWALS HEALTH CARE L (AGARWALEYE) and SUN PHARMACEUTICAL IND L (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SUN PHARMACEUTICAL IND L leads AGARWALEYE vs SUNPHARMA on 12 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

115.69
P/E ratio
40.40
7.46
P/B ratio
5.57
0.00%
Dividend yield
0.83%
₹4.20
EPS
₹47.84

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

6.81%
Return on equity
16.00%
11.00%
Return on capital
21.00%
27.00%
EBITDA margin
30.00%
8.08%
Net margin
19.69%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

26.89%
Revenue CAGR (3Y)
10.03%
17.71%
Profit CAGR (3Y)
10.57%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹15,492 Cr
Market cap
₹4.64L Cr
₹2,080 Cr
Revenue
₹58,462 Cr
₹168 Cr
Net profit
₹11,509 Cr
0.53
Debt / equity
0.06
DR AGARWALS HEALTH CARE L
  • ["Stock is trading at 7.53 times its book value", "Though the company is reporting repeated profits, it is not paying out dividend", "Company has a low return on equity of 6.11% over last 3 years."]
SUN PHARMACEUTICAL IND L
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
DR AGARWALS HEALTH CARE L full analysis SUN PHARMACEUTICAL IND L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.